BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: McEuen K, Borlak J, Tong W, Chen M. Associations of Drug Lipophilicity and Extent of Metabolism with Drug-Induced Liver Injury.Int J Mol Sci. 2017;18. [PMID: 28640208 DOI: 10.3390/ijms18071335] [Cited by in Crossref: 32] [Cited by in F6Publishing: 24] [Article Influence: 6.4] [Reference Citation Analysis]
Number Citing Articles
1 Raschi E, De Ponti F. Strategies for Early Prediction and Timely Recognition of Drug-Induced Liver Injury: The Case of Cyclin-Dependent Kinase 4/6 Inhibitors. Front Pharmacol 2019;10:1235. [PMID: 31708776 DOI: 10.3389/fphar.2019.01235] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
2 Chi ZC. Research status and progress of drug induced liver injury. Shijie Huaren Xiaohua Zazhi 2021; 29(16): 915-925 [DOI: 10.11569/wcjd.v29.i16.915] [Reference Citation Analysis]
3 Yang CX, Yao DM. Research advances in pathogenesis and diagnostic markers of drug-induced liver injury. Shijie Huaren Xiaohua Zazhi 2021; 29(13): 726-732 [DOI: 10.11569/wcjd.v29.i13.726] [Reference Citation Analysis]
4 Mach M, Bazydło-Guzenda K, Buda P, Matłoka M, Dzida R, Stelmach F, Gałązka K, Wąsińska-Kałwa M, Smuga D, Hołowińska D, Dawid U, Gurba-Bryśkiewicz L, Wiśniewski K, Dubiel K, Pieczykolan J, Wieczorek M. Discovery and development of CPL207280 as new GPR40/FFA1 agonist. Eur J Med Chem 2021;226:113810. [PMID: 34537444 DOI: 10.1016/j.ejmech.2021.113810] [Reference Citation Analysis]
5 Teschke R, Danan G. The LiverTox Paradox-Gaps between Promised Data and Reality Check. Diagnostics (Basel) 2021;11:1754. [PMID: 34679453 DOI: 10.3390/diagnostics11101754] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
6 Teschke R, Danan G. Idiosyncratic Drug Induced Liver Injury, Cytochrome P450, Metabolic Risk Factors and Lipophilicity: Highlights and Controversies. Int J Mol Sci 2021;22:3441. [PMID: 33810530 DOI: 10.3390/ijms22073441] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
7 Danan G, Teschke R. Drug-Induced Liver Injury: Why is the Roussel Uclaf Causality Assessment Method (RUCAM) Still Used 25 Years After Its Launch? Drug Saf. 2018;41:735-743. [PMID: 29502198 DOI: 10.1007/s40264-018-0654-2] [Cited by in Crossref: 44] [Cited by in F6Publishing: 41] [Article Influence: 11.0] [Reference Citation Analysis]
8 Krasavin M, Lukin A, Bakholdina A, Zhurilo N, Onopchenko O, Borysko P, Zozulya S, Moore D, Tikhonova IG. Continued SAR exploration of 1,2,4-thiadiazole-containing scaffolds in the design of free fatty acid receptor 1 (GPR40) agonists. European Journal of Medicinal Chemistry 2017;140:229-38. [DOI: 10.1016/j.ejmech.2017.09.019] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
9 European Association for the Study of the Liver;  Clinical Practice Guideline Panel: Chair;  Panel members;  EASL Governing Board representative. EASL Clinical Practice Guidelines: Drug-induced liver injury. J Hepatol. 2019;70:1222-1261. [PMID: 30926241 DOI: 10.1016/j.jhep.2019.02.014] [Cited by in Crossref: 198] [Cited by in F6Publishing: 155] [Article Influence: 66.0] [Reference Citation Analysis]
10 Schleiff MA, Payakachat S, Schleiff BM, Swamidass SJ, Boysen G, Miller GP. Impacts of diphenylamine NSAID halogenation on bioactivation risks. Toxicology 2021;458:152832. [PMID: 34107285 DOI: 10.1016/j.tox.2021.152832] [Reference Citation Analysis]
11 Leeson PD. Impact of Physicochemical Properties on Dose and Hepatotoxicity of Oral Drugs. Chem Res Toxicol 2018;31:494-505. [PMID: 29722540 DOI: 10.1021/acs.chemrestox.8b00044] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 4.3] [Reference Citation Analysis]
12 Kalgutkar AS, Driscoll JP. Is there enough evidence to classify cycloalkyl amine substituents as structural alerts? Biochem Pharmacol 2020;174:113796. [PMID: 31926938 DOI: 10.1016/j.bcp.2020.113796] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
13 Fu L, Liu L, Yang Z, Li P, Ding J, Yun Y, Lu A, Hou T, Cao D. Systematic Modeling of log D7.4 Based on Ensemble Machine Learning, Group Contribution, and Matched Molecular Pair Analysis. J Chem Inf Model 2020;60:63-76. [DOI: 10.1021/acs.jcim.9b00718] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 4.3] [Reference Citation Analysis]
14 Shi W, Jiang Y, Zhao DS, Jiang LL, Liu FJ, Wu ZT, Li ZQ, Wang LL, Zhou J, Li P, Li HJ. Metabolomic-transcriptomic landscape of 8-epidiosbulbin E acetate -a major diterpenoid lactone from Dioscorea bulbifera tuber induces hepatotoxicity. Food Chem Toxicol 2020;135:110887. [PMID: 31626840 DOI: 10.1016/j.fct.2019.110887] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
15 Teschke R, Danan G. Molecular Research on Drug Induced Liver Injury. Int J Mol Sci 2018;19:E216. [PMID: 29324638 DOI: 10.3390/ijms19010216] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
16 Kawaguchi M, Nukaga T, Sekine S, Takemura A, Susukida T, Oeda S, Kodama A, Hirota M, Kouzuki H, Ito K. Mechanism-based integrated assay systems for the prediction of drug-induced liver injury. Toxicol Appl Pharmacol 2020;394:114958. [PMID: 32198022 DOI: 10.1016/j.taap.2020.114958] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
17 Abreu Diaz AM, Drumeva GO, Laporte P, Alonso Martinez LM, Petrenyov DR, Carrier JF, DaSilva JN. Evaluation of the high affinity [18F]fluoropyridine-candesartan in rats for PET imaging of renal AT1 receptors. Nucl Med Biol 2021;96-97:41-9. [PMID: 33798796 DOI: 10.1016/j.nucmedbio.2021.03.003] [Reference Citation Analysis]
18 Wurm KW, Bartz F, Schulig L, Bodtke A, Bednarski PJ, Link A. Modifications of the Triaminoaryl Metabophore of Flupirtine and Retigabine Aimed at Avoiding Quinone Diimine Formation. ACS Omega. [DOI: 10.1021/acsomega.1c07103] [Reference Citation Analysis]
19 Kalgutkar AS. Designing around Structural Alerts in Drug Discovery. J Med Chem 2020;63:6276-302. [PMID: 31497963 DOI: 10.1021/acs.jmedchem.9b00917] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 8.3] [Reference Citation Analysis]
20 Teschke R. Idiosyncratic DILI: Analysis of 46,266 Cases Assessed for Causality by RUCAM and Published From 2014 to Early 2019. Front Pharmacol 2019;10:730. [PMID: 31396080 DOI: 10.3389/fphar.2019.00730] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 8.7] [Reference Citation Analysis]
21 Barnhill MS, Real M, Lewis JH. Latest advances in diagnosing and predicting DILI: what was new in 2017? Expert Rev Gastroenterol Hepatol 2018;12:1033-43. [PMID: 30111182 DOI: 10.1080/17474124.2018.1512854] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
22 Shimizu Y, Sasaki T, Takeshita JI, Watanabe M, Shizu R, Hosaka T, Yoshinari K. Identification of average molecular weight (AMW) as a useful chemical descriptor to discriminate liver injury-inducing drugs. PLoS One 2021;16:e0253855. [PMID: 34170966 DOI: 10.1371/journal.pone.0253855] [Reference Citation Analysis]
23 Tillmann HL, Suzuki A, Barnhart HX, Serrano J, Rockey DC. Tools for causality assessment in drug-induced liver disease. Curr Opin Gastroenterol 2019;35:183-90. [PMID: 30865042 DOI: 10.1097/MOG.0000000000000526] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
24 Real M, Barnhill MS, Higley C, Rosenberg J, Lewis JH. Drug-Induced Liver Injury: Highlights of the Recent Literature. Drug Saf 2019;42:365-87. [PMID: 30343418 DOI: 10.1007/s40264-018-0743-2] [Cited by in Crossref: 36] [Cited by in F6Publishing: 36] [Article Influence: 18.0] [Reference Citation Analysis]
25 Nunes DRDCMA, Monteiro CSDJ, dos Santos JL. Herb-Induced Liver Injury—A Challenging Diagnosis. Healthcare 2022;10:278. [DOI: 10.3390/healthcare10020278] [Reference Citation Analysis]
26 Thakkar S, Li T, Liu Z, Wu L, Roberts R, Tong W. Drug-induced liver injury severity and toxicity (DILIst): binary classification of 1279 drugs by human hepatotoxicity. Drug Discov Today 2020;25:201-8. [PMID: 31669330 DOI: 10.1016/j.drudis.2019.09.022] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 6.7] [Reference Citation Analysis]
27 Ashby K, Zhuang W, González-Jimenez A, Alvarez-Alvarez I, Lucena MI, Andrade RJ, Aithal GP, Suzuki A, Chen M. Elevated bilirubin, alkaline phosphatase at onset, and drug metabolism are associated with prolonged recovery from DILI. J Hepatol 2021;75:333-41. [PMID: 33845060 DOI: 10.1016/j.jhep.2021.03.021] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
28 Saravanakumar A, Sadighi A, Ryu R, Akhlaghi F. Physicochemical Properties, Biotransformation, and Transport Pathways of Established and Newly Approved Medications: A Systematic Review of the Top 200 Most Prescribed Drugs vs. the FDA-Approved Drugs Between 2005 and 2016. Clin Pharmacokinet 2019;58:1281-94. [PMID: 30972694 DOI: 10.1007/s40262-019-00750-8] [Cited by in Crossref: 32] [Cited by in F6Publishing: 29] [Article Influence: 16.0] [Reference Citation Analysis]
29 Shin HK, Kang MG, Park D, Park T, Yoon S. Development of Prediction Models for Drug-Induced Cholestasis, Cirrhosis, Hepatitis, and Steatosis Based on Drug and Drug Metabolite Structures. Front Pharmacol 2020;11:67. [PMID: 32116729 DOI: 10.3389/fphar.2020.00067] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]